Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Top Cited Papers
Open Access
- 17 December 2010
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 129 (1), 245-255
- https://doi.org/10.1002/ijc.25864
Abstract
Angiogenesis, a critical driver of tumor development, is controlled by interconnected signaling pathways. Vascular endothelial growth factor receptor (VEGFR) 2 and tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2 play crucial roles in the biology of normal and tumor vasculature. Regorafenib (BAY 73-4506), a novel oral multikinase inhibitor, potently inhibits these endothelial cell kinases in biochemical and cellular kinase phosphorylation assays. Furthermore, regorafenib inhibits additional angiogenic kinases (VEGFR1/3, platelet-derived growth factor receptor-β and fibroblast growth factor receptor 1) and the mutant oncogenic kinases KIT, RET and B-RAF. The antiangiogenic effect of regorafenib was demonstrated in vivo by dynamic contrast-enhanced magnetic resonance imaging. Regorafenib administered once orally at 10 mg/kg significantly decreased the extravasation of Gadomer in the vasculature of rat GS9L glioblastoma tumor xenografts. In a daily (qd)×4 dosing study, the pharmacodynamic effects persisted for 48 hr after the last dosing and correlated with tumor growth inhibition (TGI). A significant reduction in tumor microvessel area was observed in a human colorectal xenograft after qd×5 dosing at 10 and 30 mg/kg. Regorafenib exhibited potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages observed in breast MDA-MB-231 and renal 786-O carcinoma models. Pharmacodynamic analyses of the breast model revealed strong reduction in staining of proliferation marker Ki-67 and phosphorylated extracellular regulated kinases 1/2. These data demonstrate that regorafenib is a well-tolerated, orally active multikinase inhibitor with a distinct target profile that may have therapeutic benefit in human malignancies.Keywords
This publication has 45 references indexed in Scilit:
- Tie2 in Tumor Endothelial Signaling and Survival: Implications for Antiangiogenic TherapyMolecular Cancer Research, 2009
- Targeting RET for thyroid cancer therapyBiochemical Pharmacology, 2009
- Angiogenic Switch of Angiopietins-Tie2 System and Its Prognostic Value in Bladder CancerClinical Cancer Research, 2008
- Modes of resistance to anti-angiogenic therapyNature Reviews Cancer, 2008
- Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalizationMicrovascular Research, 2007
- Angiopoietin-2 Stimulates Breast Cancer Metastasis through the α5β1 Integrin-Mediated PathwayCancer Research, 2007
- KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal TumorsThe American Journal of Pathology, 2000
- Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endotheliumNature, 1995
- Failure of blood-island formation and vasculogenesis in Flk-1-deficient miceNature, 1995
- Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell LineBiochemical and Biophysical Research Communications, 1995